Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00748605 · ClinicalTrials.gov registry record · Phase 2
Phase IIb One Year Efficacy and Safety Study of S-2367 in Obese Subjects With Initial 6-Week Low Calorie Diet
A Phase 2 study, sponsored by Shionogi.
- Completed
- Registry status
- Phase 2
- Development phase
- 842
- Enrollment target
NCT00748605: Completed Phase 2 study, sponsored by Shionogi.
NCT00748605 is a Phase 2 study that has completed, run by Shionogi. The registered enrollment target is 842 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (533% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00748605, a Phase 2 study, has completed, sponsored by Shionogi.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 842 participants
- Enrollment target
Study Summary
1. To evaluate the weight loss effect of 1600 mg/day S-2367 administered orally once daily with the morning meal after a 6-week low calorie diet (LCD) of 950 kcal/day with or without S-2367 followed by 54 weeks while on a 800 kcal deficit reduced calorie diet (RCD) compared with placebo in medically stable and otherwise healthy obese male and female subjects 2. To evaluate the safety and tolerability of 1600 mg/day S-2367 administered orally once daily with the morning meal after a 6-week LCD with or without S-2367 followed by 54 weeks on a RCD compared with placebo in medically stable and otherwise healthy obese male and female subjects 3. To evaluate the steady-state/trough pharmacokinetics of 1600 mg/day S-2367 administered orally once daily with the morning meal after a 6-week LCD with or without S-2367 followed by 54 weeks on a RCD in obese male and female subjects 4. To evaluate the weight loss effect of 1600 mg/day S-2367 administered orally once daily with the morning meal during an initial 6-week LCD compared with placebo in medically stable and otherwise healthy obese male and female subjects
Interventions
- DRUG S-2367 Placebo
- DRUG S-2367 1600 mg q.d. 54 Weeks
- DRUG S-2367 1600 mg q.d. 60 weeks
- OTHER LCD (low calorie diet)
- OTHER RCD (reduced calorie diet)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 842 participants |
| Start Date | 2007-06 |
| Est. Completion | 2009-01 |
| Phase | Phase 2 |
What the finished NCT00748605 record still lists
NCT00748605 is an interventional study that assigns participants to a tested intervention. The registered 842 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (533% higher).
The record links to 0 conditions, and to 5 interventions - of which S-2367 Placebo is the first listed.
NCT00748605 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00748605 about?
NCT00748605 is a clinical study titled "Phase IIb One Year Efficacy and Safety Study of S-2367 in Obese Subjects With Initial 6-Week Low Calorie Diet". 1. To evaluate the weight loss effect of 1600 mg/day S-2367 administered orally once daily with the morning meal after a 6-week low calorie diet (LCD) of 950 kcal/day with or without S-2367 followed by 54 weeks while on a 800 kcal deficit reduced calorie diet (RCD) compared with placebo in medically...
What is the current status of trial NCT00748605?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 842 participants. The study started on 2007-06. Estimated completion is 2009-01.
What interventions are being tested in trial NCT00748605?
The interventions under investigation include: S-2367 Placebo (DRUG), S-2367 1600 mg q.d. 54 Weeks (DRUG), S-2367 1600 mg q.d. 60 weeks (DRUG), LCD (low calorie diet) (OTHER), RCD (reduced calorie diet) (OTHER).
Who is sponsoring clinical trial NCT00748605?
This trial is sponsored by Shionogi, which has 54 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00748605's enrollment target sits among peer trials
842 36th of 2000 higher than 1,965 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06027788 · 842 participants · NA
CTSN Embolic Protection Trial
- NCT06439979 · 843 participants · NA
Rural Adult and Youth Sun Protection Study
- NCT06747949 · 844 participants · Phase 3
A Long-term Extension Study of Dazodalibep in Participants With Sjögren's Syndrome (SS)
- NCT04831580 · 840 participants · NA
A Trial of Robotic Versus Open Hysterectomy Surgery in Cervix Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia